Association of Pre-diagnostic Antibody Responses to Escherichia coli and Bacteroides fragilis Toxin Proteins with Colorectal Cancer in a European Cohort
Autor: | Christina C. Dahm, Inger T. Gram, Elom K. Aglago, Eva Ardanaz, Bas Bueno-de-Mesquita, Krasimira Aleksandrova, David J. Hughes, Joseph A. Rothwell, Anja Olsen, Renée Turzanski-Fortner, Elisabete Weiderpass, Mazda Jenab, Valeria Pala, R. Tumino, Marie-Christine Boutron-Ruault, Thyra Löwenmark, Semi Zouiouich, María Dolores Chirlaque, Rudolf Kaaks, Gianluca Severi, Carlotta Sacerdote, Jill Werner, Carla H. van Gils, Marko Lukic, Salvatore Panico, Richard Palmquist, Heinz Freisling, Ruth C. Travis, Matthias B. Schulze, Núria Sala, Tim Waterboer, María José Pérez, Amanda J. Cross, Alicia K Heath, Julia Butt, Veronika Fedirko, Domenico Palli, Anne Tjønneland |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Male Colorectal cancer serology RC799-869 medicine.disease_cause Serology Bacteroides fragilis 0302 clinical medicine Odds Ratio Prospective Studies Escherichia coli Infections Gastroenterology food and beverages Metalloendopeptidases Diseases of the digestive system. Gastroenterology Middle Aged Bacteroides Infections Antibodies Bacterial Europe Prospective Infectious Diseases bacteroides fragilis Cohort 030211 gastroenterology & hepatology Female Colorectal Neoplasms 0605 Microbiology Research Article Research Paper Microbiology (medical) Adult Colon Bacterial Toxins Gastroenterology and Hepatology Biology Microbiology 03 medical and health sciences Càncer colorectal medicine Gastroenterologi Escherichia coli Biomarkers Tumor Humans VDP::Medisinske Fag: 700 Bacteroides fragilis toxin Aged Antigens Bacterial Bacils prospective medicine.disease biology.organism_classification VDP::Medical disciplines: 700 Bacillus (Bacteria) 030104 developmental biology Antibody response Escheríchia coli |
Zdroj: | Gut Microbes article-version (VoR) Version of Record Butt, J, Jenab, M, Werner, J, Fedirko, V, Weiderpass, E, Dahm, C C, Tjønneland, A, Olsen, A, Boutron-Ruault, M-C, Rothwell, J A, Severi, G, Kaaks, R, Turzanski-Fortner, R, Aleksandrova, K, Schulze, M, Palli, D, Pala, V, Panico, S, Tumino, R, Sacerdote, C, Bueno-de-Mesquita, B, Van Gils, C H, Gram, I T, Lukic, M, Sala, N, Sánchez Pérez, M J, Ardanaz, E, Chirlaque, M-D, Palmquist, R, Löwenmark, T, Travis, R C, Heath, A, Cross, A J, Freisling, H, Zouiouich, S, Aglago, E, Waterboer, T & Hughes, D J 2021, ' Association of Pre-diagnostic Antibody Responses to Escherichia coli and Bacteroides fragilis Toxin Proteins with Colorectal Cancer in a European Cohort ', Gut Microbes, vol. 13, no. 1, pp. 1-14 . https://doi.org/10.1080/19490976.2021.1903825 Gut Microbes, Vol 13, Iss 1 (2021) Dipòsit Digital de la UB Universidad de Barcelona Digibug. Repositorio Institucional de la Universidad de Granada instname Butt, J, Jenab, M, Werner, J, Fedirko, V, Weiderpass, E, Dahm, C C, Tjønneland, A, Olsen, A, Boutron-Ruault, M C, Rothwell, J A, Severi, G, Kaaks, R, Turzanski-Fortner, R, Aleksandrova, K, Schulze, M, Palli, D, Pala, V, Panico, S, Tumino, R, Sacerdote, C, Bueno-de-Mesquita, B, Van Gils, C H, Gram, I T, Lukic, M, Sala, N, Sánchez Pérez, M J, Ardanaz, E, Chirlaque, M D, Palmquist, R, Löwenmark, T, Travis, R C, Heath, A, Cross, A J, Freisling, H, Zouiouich, S, Aglago, E, Waterboer, T & Hughes, D J 2021, ' Association of Pre-diagnostic Antibody Responses to Escherichia coli and Bacteroides fragilis Toxin Proteins with Colorectal Cancer in a European Cohort ', Gut Microbes, vol. 13, no. 1 . https://doi.org/10.1080/19490976.2021.1903825 |
ISSN: | 1949-0984 1949-0976 |
Popis: | The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by the Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, and Institut National de la Santé et de la Recherche Médicale (INSERM) (France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); the Sicilian Government, AIRE ONLUS Ragusa, AVIS Ragusa, Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), and Statistics Netherlands (the Netherlands); Nordic Centre of Excellence programme on Food, Nutrition and Health. (Norway); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia, Navarra, and the Catalan Institute of Oncology (Barcelona), Spain; Swedish Cancer Society, Swedish Scientific Council, and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (C864/A14136 to EPIC-Norfolk; C8221/A19170, C570/A16491 and C8221/ A290170 to EPIC-Oxford), Medical Research Council (MR/ N003284/1 and MC-UU_12015/1 to EPIC-Norfolk, MR/ M012190/1 to EPIC-Oxford (UK). The funding sources had no influence on the design of the study; the collection, analysis, and interpretation of data; the writing of the report; or the decision to submit the paper for publication.Support for this study was also provided by the COST Action CA17118 supported by COST (European Cooperation in Science and Technology, www.cost.eu) to DJH. Experimental evidence has implicated genotoxic Escherichia coli (E. coli) and enterotoxigenic Bacteroides fragilis (ETBF) in the development of colorectal cancer (CRC). However, evidence from epidemiological studies is sparse. We therefore assessed the association of serological markers of E. coli and ETBF exposure with odds of developing CRC in the European Prospective Investigation into Nutrition and Cancer (EPIC) study. Serum samples of incident CRC cases and matched controls (n = 442 pairs) were analyzed for immunoglobulin (Ig) A and G antibody responses to seven E. coli proteins and two isoforms of the ETBF toxin via multiplex serology. Multivariable-adjusted conditional logistic regression analyses were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association of sero-positivity to E. coli and ETBF with CRC. The IgA-positivity of any of the tested E. coli antigens was associated with higher odds of developing CRC (OR: 1.42; 95% CI: 1.05–1.91). Dual-positivity for both IgA and IgG to E. coli and ETBF was associated with >1.7-fold higher odds of developing CRC, with a significant association only for IgG (OR: 1.75; 95% CI: 1.04, 2.94). This association was more pronounced when restricted to the proximal colon cancers (OR: 2.62; 95% CI: 1.09, 6.29) compared to those of the distal colon (OR: 1.24; 95% CI: 0.51, 3.00) (pheterogeneity = 0.095). Sero-positivity to E. coli and ETBF was associated with CRC development, suggesting that co-infection of these bacterial species may contribute to colorectal carcinogenesis. These findings warrant further exploration in larger prospective studies and within different population groups. European Commission (DG-SANCO) International Agency for Research on Cancer Danish Cancer Society (Denmark) Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, and Institut National de la Santé et de la Recherche Médicale (INSERM) (France) Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, and Federal Ministry of Education and Research (Germany) Hellenic Health Foundation (Greece) Sicilian Government, AIRE ONLUS Ragusa, AVIS Ragusa, Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, and National Research Council (Italy) Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), and Statistics Netherlands (the Netherlands) Nordic Centre of Excellence programme on Food, Nutrition and Health. (Norway) Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia, Navarra, and the Catalan Institute of Oncology (Barcelona), Spain Swedish Cancer Society, Swedish Scientific Council, and County Councils of Skåne and Västerbotten (Sweden) Cancer Research UK (C864/A14136 to EPIC-Norfolk; C8221/A19170, C570/A16491 and C8221/ A290170 to EPIC-Oxford), Medical Research Council (MR/ N003284/1 and MC-UU_12015/1 to EPIC-Norfolk, MR/ M012190/1 to EPIC-Oxford (UK) COST Action CA17118 supported by COST (European Cooperation in Science and Technology) |
Databáze: | OpenAIRE |
Externí odkaz: |